{"nctId":"NCT00250432","briefTitle":"A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults (0991-801)(COMPLETED)","startDateStruct":{"date":"2006-01"},"conditions":["Invasive Candidiasis"],"count":204,"armGroups":[{"label":"1","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: caspofungin acetate"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: caspofungin acetate"]}],"interventions":[{"name":"caspofungin acetate","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Clinical and Laboratory evidence of blood stream \\&/or systemic candida infections\n\nExclusion Criteria:\n\n* Possible candida contamination\n* Candida colonization (non invasive infection), urine, cardiac, bone or brain and prosthetic device infections\n* Acute or moderately severe liver disease\n* Abnormal liver function tests\n* Abnormal blood clotting for patients on blood thinners","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Patients Who Develop Significant Drug-related Adverse Events.","description":"Number of patients with at least 1 significant drug-related adverse event (serious drug-related or drug-related adverse events leading to caspofungin discontinuation) while on caspofungin study therapy or during the immediate 14-day post-caspofungin therapy period.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With a Favorable Overall Response.","description":"Number of patients with a favorable overall response, defined as a clinical response of \"cure\" or \"apparent cure\" along with a microbiological response of \"eradication\" or \"presumptive eradication\" at the End of Caspofungin Therapy.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null},{"groupId":"OG001","value":"74","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":46},"commonTop":["Blood Alkaline Phosphatase Increased","Vomiting","Aspartate Aminotransferase Increased","Blood Potassium Decreased","Diarrhea"]}}}